Formycon Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Stefan Glombitza

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

CEO

Stefan Glombitza (59 yo)

8.1yrs

Tenure

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza served as Chief Operating Officer of Formycon...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stefan Glombitza	CEO & Member of Executive Board	8.1yrs	geen gegevens	geen gegevens
Friedrich-Wilhelm Steinweg	Co-Founder	no data	geen gegevens	geen gegevens
Nicolas Combe	Co-Founder	no data	geen gegevens	geen gegevens
Enno Spillner	CFO & Member of Management Board	1.6yrs	geen gegevens	geen gegevens
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	2.3yrs	geen gegevens	geen gegevens
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	2.4yrs	geen gegevens	geen gegevens
Sabrina Muller	Director of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FYB wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bernhard Hampl	Member of Advisory Board	10.7yrs	geen gegevens	geen gegevens
Gerhard Schaefer	Member of Advisory Board	11yrs	geen gegevens	geen gegevens
Colin Bond	Deputy Chairman of the Supervisory Board	less than a year	geen gegevens	geen gegevens
Nicholas Haggar	Member of the Supervisory Board	less than a year	geen gegevens	geen gegevens
Johannes Buchner	Member of Advisory Board	8.8yrs	geen gegevens	geen gegevens
Thomas Siklosi	Member of Advisory Board	6.3yrs	geen gegevens	geen gegevens
Klaus Rohrig	Member of Supervisory Board	3.9yrs	geen gegevens	geen gegevens
Wolfgang Essler	Chairman of the Supervisory Board	1.3yrs	geen gegevens	geen gegevens
Bodo Coldewey	Member of the Supervisory Board	less than a year	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FYB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Formycon Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Formycon AG Appoints Colin Bond as Director

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Investor sentiment improves as stock rises 15%

Price target decreased by 8.7% to €87.00

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 8.9% to €105

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

New minor risk - Share price stability

Price target decreased by 7.5% to €107

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 8.8% to €115

New minor risk - Share price stability

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings: EPS and revenues miss analyst expectations

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Price target decreased to €70.00

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

New 90-day high: €75.40

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Price target raised to €46.45

New 90-day high: €51.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

New 90-day high: €37.50

New 90-day high: €30.70

First half earnings released

Price target raised to €36.28

New 90-day high - €27.20

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd